Findlay Park Partners’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $76.1M | Buy |
154,740
+44,000
| +40% | +$23.9M | 1.06% | 41 |
|
|
2025
Q4 | $64.2M | Sell |
110,740
-205,880
| -65% | -$116M | 0.82% | 48 |
|
|
2025
Q3 | $154M | Sell |
316,620
-5,600
| -2% | -$2.61M | 1.61% | 28 |
|
|
2025
Q2 | $131M | Sell |
322,220
-11,600
| -3% | -$4.85M | 1.35% | 35 |
|
|
2025
Q1 | $166M | Buy |
333,820
+4,400
| +1% | +$2.38M | 1.71% | 29 |
|
|
2024
Q4 | $171M | Buy |
329,420
+4,800
| +1% | +$2.64M | 1.7% | 26 |
|
|
2024
Q3 | $201M | Buy |
324,620
+36,700
| +13% | +$21.7M | 1.89% | 22 |
|
|
2024
Q2 | $159M | Sell |
287,920
-2,200
| -0.8% | -$1.26M | 1.5% | 30 |
|
|
2024
Q1 | $169M | Sell |
290,120
-63,300
| -18% | -$35.5M | 1.55% | 29 |
|
|
2023
Q4 | $188M | Sell |
353,420
-3,824
| -1% | -$1.85M | 1.84% | 23 |
|
|
2023
Q3 | $181M | Buy |
357,244
+76,231
| +27% | +$40.6M | 1.94% | 22 |
|
|
2023
Q2 | $147M | Sell |
281,013
-12,559
| -4% | -$6.78M | 1.51% | 29 |
|
|
2023
Q1 | $169M | Sell |
293,572
-14,753
| -5% | -$8.32M | 1.79% | 24 |
|
|
2022
Q4 | $170M | Buy |
308,325
+84,960
| +38% | +$45M | 1.85% | 22 |
|
|
2022
Q3 | $113M | Sell |
223,365
-134,038
| -38% | -$75M | 1.12% | 33 |
|
|
2022
Q2 | $194M | Sell |
357,403
-1,718
| -0.5% | -$946K | 1.81% | 20 |
|
|
2022
Q1 | $212M | Hold |
359,121
| – | – | 1.6% | 24 |
|
|
2021
Q4 | $240M | Hold |
359,121
| – | – | 1.6% | 25 |
|
|
2021
Q3 | $205M | Sell |
359,121
-1,587
| -0.4% | -$871K | 1.41% | 31 |
|
|
2021
Q2 | $182M | Sell |
360,708
-8,718
| -2% | -$4.11M | 1.24% | 34 |
|
|
2021
Q1 | $169M | Sell |
369,426
-193,542
| -34% | -$92.4M | 1.17% | 31 |
|
|
2020
Q4 | $262M | Sell |
562,968
-56,007
| -9% | -$26.3M | 1.82% | 21 |
|
|
2020
Q3 | $273M | Sell |
618,975
-31,025
| -5% | -$12.8M | 1.89% | 22 |
|
|
2020
Q2 | $236M | Sell |
650,000
-106,273
| -14% | -$35.6M | 1.84% | 19 |
|
|
2020
Q1 | $214M | Hold |
756,273
| – | – | 2.06% | 17 |
|
|
2019
Q4 | $246M | Hold |
756,273
| – | – | 1.92% | 19 |
|
|
2019
Q3 | $220M | Hold |
756,273
| – | – | 1.93% | 22 |
|
|
2019
Q2 | $222M | Sell |
756,273
-118,727
| -14% | -$32.7M | 1.98% | 21 |
|
|
2019
Q1 | $240M | Hold |
875,000
| – | – | 2.2% | 21 |
|
|
2018
Q4 | $196M | Sell |
875,000
-425,000
| -33% | -$99.7M | 1.86% | 24 |
|
|
2018
Q3 | $317M | Sell |
1,300,000
-225,000
| -15% | -$51.8M | 2.82% | 14 |
|
|
2018
Q2 | $316M | Buy |
1,525,000
+125,000
| +9% | +$26.5M | 3.03% | 12 |
|
|
2018
Q1 | $289M | Sell |
1,400,000
-677,151
| -33% | -$142M | 2.88% | 14 |
|
|
2017
Q4 | $394M | Sell |
2,077,151
-30,000
| -1% | -$5.75M | 3.75% | 5 |
|
|
2017
Q3 | $399M | Sell |
2,107,151
-150,000
| -7% | -$27.2M | 3.94% | 4 |
|
|
2017
Q2 | $394M | Buy |
2,257,151
+225,000
| +11% | +$37.8M | 4.02% | 3 |
|
|
2017
Q1 | $312M | Buy |
2,032,151
+350,000
| +21% | +$53.5M | 3.31% | 7 |
|
|
2016
Q4 | $237M | Buy |
1,682,151
+390,000
| +30% | +$57.5M | 2.89% | 11 |
|
|
2016
Q3 | $206M | Buy |
1,292,151
+135,000
| +12% | +$20.8M | 2.38% | 17 |
|
|
2016
Q2 | $171M | Buy |
1,157,151
+190,000
| +20% | +$28M | 1.96% | 21 |
|
|
2016
Q1 | $137M | Buy |
967,151
+207,151
| +27% | +$27.8M | 1.56% | 26 |
|
|
2015
Q4 | $108M | Buy |
+760,000
| New | +$101M | 1.23% | 31 |
|
Other funds holding TMO
VCM
Findlay Park Partners's TMO Position: Q1 2026 in Review
Findlay Park Partners increased its Thermo Fisher Scientific (TMO) stake by 40% in Q1 2026, buying an estimated $23.9M and bringing the position to 154,740 shares worth $76.1M. The position accounts for 1.06% of the portfolio, ranked #41.
Findlay Park Partners first reported a position in TMO in Q4 2015 and has held it in 42 quarters since. The position peaked at $399M in Q3 2017. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Findlay Park Partners held 154,740 shares of Thermo Fisher Scientific worth $76.1M as of Q1 2026.
- Findlay Park Partners bought 44,000 Thermo Fisher Scientific shares in Q1 2026, an estimated $23.9M.
- Thermo Fisher Scientific made up 1.06% of Findlay Park Partners's portfolio in Q1 2026, its #41 holding.
- Findlay Park Partners first reported a position in Thermo Fisher Scientific in Q4 2015 and has held it in 42 quarters since.
- Findlay Park Partners's Thermo Fisher Scientific position peaked at $399M in Q3 2017.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Findlay Park Partners's 13F filing for Q1 2026, filed 13 May 2026.